Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: sigma receptor modulators - Anavex Life Sciences

Next Previous
X
Search
Drug Profile

Research programme: sigma receptor modulators - Anavex Life Sciences

Alternative Names: ANAVEX 1005; ANAVEX 1007; ANAVEX 1067; ANAVEX 1079; ANAVEX 1519; ANAVEX 27-1041; ANAVEX 28-1078; ANAVEX 30-1022; ANAVEX 35-3016; ANAVEX 40-1042; ANAVEX 7-1037; ANAVEX 8-142; ANAVEX™ 1066; Cancer therapeutics - Anavex Life Sciences; Sigmaceptor-C™ programme

Latest Information Update: 04 Jan 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anavex Life Sciences
  • Class Analgesics; Antineoplastics; Small molecules
  • Mechanism of Action Chloride channel modulators; Muscarinic M3 receptor antagonists; Sigma-1 receptor agonists; Sigma-1 receptor antagonists; Sigma-2 receptor agonists; Sigma-2 receptor antagonists; Sodium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Acute pain; Malignant melanoma; Neuropathic pain; Ovarian cancer; Pain; Pancreatic cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 04 Jan 2023 Discontinued - Preclinical for Acute pain in Switzerland (unspecified route) (Anavex Life Sciences pipeline, January 2023)
  • 04 Jan 2023 Discontinued - Preclinical for Malignant melanoma in Switzerland (unspecified route) (Anavex Life Sciences pipeline, January 2023)
  • 04 Jan 2023 Discontinued - Preclinical for Neuropathic pain in Switzerland (unspecified route) (Anavex Life Sciences pipeline, January 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top